Lumida
/GOCOQ
⌘K
GOCOQ

GOCOQ

GOCOQ
$0.35USD-1.14%-0.00 today

MARKET CAP

0

P/E (TTM)

FWD P/E

DAY RANGE

$0 – $0

52W RANGE

$0
$7

AI Summary

Stalk
Sell NowHigh

GOCOQ remains in a Stage 4 decline, trading below all major EMAs with a clear sequence of lower highs and lower lows. Price continues to be rejected at the declining 9EMA and 20EMA resistance zone, reinforcing the bearish medium-term posture. Short-term conditions favor selling now into this resistance cluster before further downside continuation.

  • AEP 2026-focused bankruptcy restructuring aims to restore stability
  • Liquidity score 1.17 indicates sufficient reserves for near-term needs
  • Liabilities of $1–10 B vs assets of $500 M–1 B highlight deep insolvency risk
Full analysis →

The case for & against

Bull & Bear analysis

Bearish

GoHealth, Inc. (Ticker: GOCOQ) operates in the health insurance technology sector, focusing on connecting consumers with health insurance coverage. The company has faced significant challenges recently, marked by its Chapter 11 bankruptcy filing and consequent delisting from major stock exchanges. As a player in the health insurance marketplace, GoHealth's role is critical in facilitating insurance options for consumers, yet its recent financial woes reflect deeper industry issues and management challenges.

Bull says

  • AEP 2026-focused bankruptcy restructuring aims to restore stability
  • Liquidity score 1.17 indicates sufficient reserves for near-term needs
  • Dividend yield of 0.29% maintained amid restructuring drives income potential
  • Book-to-price ratio ~2.97 implies underlying asset value
  • Moderate sensitivity to interest rates and oil could boost demand if macro conditions improve

Bear says

  • Liabilities of $1–10 B vs assets of $500 M–1 B highlight deep insolvency risk
  • Revenue plunged 58% YoY; net margin sank to −190%
  • Debt/equity ~17.5x elevates refinancing pressure in rising-rate environment
  • Negative momentum & trading below key moving averages reflect bearish trend
  • Short interest 0.73 and negative sentiment signal widespread skepticism
  • Weak earnings yield, poor revision trends and high volatility undermine recovery prospects